Study details
Enrolling now
Long-term Study of Guselkumab in Children with Arthritis
Janssen Research & Development, LLC
NCT IDNCT06663332ClinicalTrials.gov data as of Apr 2026
Phase
Phase 3
Target enrollment
196
Study length
about 7.1 years
Ages
3+
Locations
4 sites in GA, IN, OH +1
About this study
Researchers are testing the safety of a medication called guselkumab in children who have arthritis, including juvenile arthritis, psoriatic arthritis, ulcerative colitis, or Crohn's disease. The trial will last for 2600 days and involve approximately 196 participants.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Guselkumab
PhasePhase 3
DrugGuselkumab
Routeinjection
Primary goalNumber of Participants with Treatment-Emergent Adverse Events as Assessment of Safety
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low7%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
guselkumab
Drug routes
injection, intravenous
Endpoints
Primary: Number of Participants with Treatment-Emergent Adverse Events as Assessment of Safety
Body systems
Dermatology, Gastroenterology, Immune, Musculoskeletal